Zydus sees vaccines, medical devices as new growth drivers

Zydus expects to outperform the Indian pharma market in FY26, while projecting single-digit growth in the US

- Jessica Jani

Zydus Lifesciences Ltd is looking to ramp up its vaccines and medtech portfolio over the next few years, the company's top executive told investors during an earnings call Tuesday evening.

The drugmaker, which announced its Q4FY25 results the same day, expects double-digit revenue growth in FY26, led by strong performance in both domestic and international markets, as well as newer businesses such as biologics, vaccines, and medtech.

"...led by strong growths in India and international markets and also our new growth themes like biologics, vaccines and all scaling up," said managing director Sharvil Patel.

The company expects to outperform the Indian pharmaceutical market in FY26, while projecting single-digit growth in the US.